RESOLUTION SUMMARIZING THE RESULTS OF THE EXPERT COUNCIL "MODERN APPROACHES TO THE TREATMENT OF HER2-NEGATIVE METASTATIC BREAST CANCER. PROSPECTS FOR THE USE OF ERIBULIN AS A PART OF COMBINATION THERAPY FOR BREAST CANCER"


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the results of the meeting of the Expert Council «Modern approaches to the treatment of HER2-negative metastatic breast cancer. Prospects for the use of eribulin as a part of combination therapy for breast cancer». The meeting was held on November 15, 2015, and discussed the modern world standards of treatment HER2-negative metastatic breast cancer (MBC); the results of clinical studies on the use of eribulin at different subtypes of breast cancer, and in combination with other drugs, as well as in other nosology, were considered; expert opinion on the prospects for the use of eribulin in a combination therapy for breast cancer based on the latest research data and clinical experience of meeting members was derived.

全文:

受限制的访问

作者简介

E. Artamonova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

L. Bolotina

MSROI n.a. P.A. Herzen - branch FSBI NMRRC of RMH Moscow

Zh. Gligorov

Sorbonne University France, Ile-de-France, Paris

N. Zhukov

FRCC CHOI n.a. Dmitry Rogachev, FSBEI HE RNSMU n.a. N.I. Pirogov of RMH Moscow

L. Zhukova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

E. Imyanitov

FSBI SRI of Oncology n.a. N.N. Petrov of RMH St. Petersburg

E. Karabina

SHCI Tula Regional Oncological Dispensary Tula

E. Kovalenko

Email: eikovalenko@mail.ru
FSBI RORC n.a. N.N. Blokhin of RMH PhD, Researcher at the Department of Study of New Anticancer Drugs Moscow

M. Lichinitser

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

L. Manzyuk

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

V. Semiglazov

FSBI SRI of Oncology n.a. N.N. Petrov of RMH SBEIHPE “North-Western State Medical University n.a. I.I. Mechnikov" of RMH St. Petersburg

T. Semiglazova

FSBI SRI of Oncology n.a. N.N. Petrov of RMH SBEIHPE “North-Western State Medical University n.a. I.I. Mechnikov" of RMH St. Petersburg

D. Stroyakovsky

Moscow City Oncological Hospital № 62 of the Moscow Healthcare Department

参考

  1. Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012 с изменениями от 28.07.2016).
  2. Kim C., Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA intern. Med. 2015;175(12):1992-94.
  3. Ellis L.M., Bernstein D.S., Voest E.E., Berlin J.D., Sargent D., Cortazar P., Garrett-Mayer E., Herbst R.S., Lilenbaum R.C., Sima C., Venook A.P., Gonen M., Schilsky R.L., Meropol N.J., Schnipper L.E. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Onc. 2014;32(12):1277-80.
  4. Cortazar I.P., Justice R., Johnson J., Sridhara R., Keegan P., Pazdur R. US Food and Drug Administration Approval Overview in Metastatic Breast Cancer. J. Clin. Oncol. 2012;30:1705-11.
  5. Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., Chollet P., Manikas A., Diéras V., Delozier T., Vladimirov V., Cardoso F., Koh H., Bougnoux P., Dutcus C.E., Seegobin S., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet. 2011;377:914-23.
  6. Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., Olivo M.S., He Y., Dutcus C.E., Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J. Clin. Oncol. 2015;33(6):594-601.
  7. Twelves C., Awada A., Cortes J., Yelle I., Velikova G., Olivo M., Song J., Dutcus C., Kaufman P. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research. 2016;10: 77-84.
  8. Twelves C., Cortes J., Vahdat L., Olivo M., He Y., Kaufman P.A., Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat. 2014;148 (3):553-61.
  9. Schöffski P., Chawla S., Maki R.G., Italiano A., Gelderblom H., Choy E., Grignani G., Camargo V., Bauer S., Rha S.Y., Blay J.Y., Hohenberger P., DAdamo D., Guo M., Chmielowski B., et al. Eribulin versus dacar-bazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-37.
  10. Partridge A.H., Rumble R.B., Carey L.A, Come S.E., Davidson N.E., Di Leo A., Gralow J., Hortobagyi G.N., Moy B., Yee D., Brundage S.B., Danso M.A., Wilcox M., Smith I.E. Chemo-and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer. J. Clin. Oncol. 2014;32:3307-29.
  11. Blum J.L., Twelves C.J., Dutcus C., et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010;San Antonio, TX. USA. P6-13-01.
  12. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-Negative Breast Cancer. N. Engl. J. Med. 2010;363:1938-48.
  13. Fan Y., Xu B.H., Yuan P., Ma F., Wang J.Y., Ding X.Y., Zhang P., Li Q., Cai R.G. Docetaxelcisplatin might be superior to docetaxelcapecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann. Oncol. 2013;24(5):1219-25.
  14. Fan F. Evaluation and Reporting of Breast Cancer after Neoadjuvant Chemotherapy. Response-guided neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol. 2013;31(29):3623-30.
  15. Cortes J., Hudgens S., Twelves C., Perez E.A., Awada A., Yelle L., McCutcheon S., Kaufman P.A., Forsythe A., Velikova G. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulinmesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res. Treat. 2015;154(3):509-20.
  16. Frasci G., Comella P., Rinaldo M., Iodice G., Di Bonito M., D'Aiuto M., Petrillo A., Lastoria S., Siani C., Comella G., D'Aiuto G. Preoperative weekly cisplatin-epirubicinpaclitaxel with GCSF support in triple-negative large operable breast cancer. Ann Oncol 2009;20(7):1185-92.
  17. von Minckwitz G., Schneeweiss A., Loibl S., et al. Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. G 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747-56.
  18. Kaklamani V.G., Jeruss J.S., Hughes E., et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015;151(3):629-38.
  19. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., Dickler M., Overmoyer B.A., Reimann J.D., Sing A.P., Langmuir V., Rugo H.S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005;23:792-99.
  20. Nasim M., et al. Phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advance/metastatic cancer. Society of Clinical Oncology (ASCO). 2012;Poster 2552.
  21. Twelves C., et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase 2 dose-confirmation study. Presented at SABCS 2014. Abstract #P3-13-04.
  22. Carreca I.U., et al. ASCO 2015, poster 199, abstr. 9540.
  23. Wilks S., Puhalla S., O'Shaughnessy J., Schwartzberg L., Berrak E., Song J., Cox D., Vahdat L. Phase 2, multicenter, single arm study of eribulin mesylate with trastuzumab as first Line therapy for locally recurrent or metastatic HER2 positive breast cancer. Clin. Breast Cancer. 2014;14:405-12.
  24. Freedman R., et al. Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer. https://clinicaltrials.gov/ct2/ show/NCT01912963.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##